View Article

  • Oral Delivery Challenges & Formulation Strategies for Glucagon Like Peptide-1 Receptor Agonists

  • 1235Research Scholar at Department of Pharmaceutics, Dr. Shivajirao Kadam College of Pharmacy, Kasabe - Digraj, Maharashtra, India

    4Research Scholar at Department of Pharmaceutics, Maratha Vidya Prasarak Samaj College of Pharmacy Nashik, Maharashtra, India                                   

Abstract

Glucagon-like peptide-1 receptor agonists are highly effective therapeutic agents for the management of type 2 diabetes mellitus & obesity due their glucose-dependent insulinotropic activity, appetite suppression, & cardiometabolic benefits. However, their clinical use has traditionally been limited injectable formulations because of poor oral bioavailability resulting from enzymatic degradation, acidic gastric conditions, low intestinal permeability, & extensive first-pass metabolism. The development of orally administered glucagon like peptide-1 receptor agonists represents a major advancement in peptide drug delivery but remains scientifically challenging. Biological/physicochemical barriers to oral delivery of GLP-1 and innovative formulation strategies designed to overcome these obstacles, including absorption enhancers, enzyme?inhibitors, nanocarriers, gastroretentive formulations and multi-mechanistic delivery systems are critically reviewed in this article. Furthermore, safety concerns, regulatory aspects and future perspectives for the oral preparation of glucagon-like peptide-1 receptor?agonists are discussed emphasizing the importance to develop creative as well as patient-friendly administration forms.

Keywords

Glucagon like peptide-1 receptor agonists; Oral peptide delivery; Absorption enhancers; SNAC; Oral semaglutide; Peptide stability..

Introduction

× Popup Image

The gastrointestinal tract’s enteroendocrine L-cells secrete the incretin hormone glucagon-like peptide-1 in response dietary intake, playing a critical role in maintenance of glucose homeostasis. Following nutrient ingestion, glucagon like peptide-1 is released in circulation & coordinates metabolic responses through endocrine, paracrine, & neuroendocrine mechanisms [1]. Physiologically, glucagon like peptide-1 improves postprandial glycaemic control & overall energy balance by enhancing glucose-dependent insulin secretion from pancreatic β-cells, suppressing glucagon release from α-cells, delaying gastric emptying, & promoting satiety via central nervous system signalling pathways [2]. Beyond glycaemic regulation, glucagon like peptide-1 signalling has been shown exert beneficial effects on β-cell preservation, insulin sensitivity, inflammatory pathways, & cardiovascular physiology, underscoring its multifaceted role in metabolic health. However, the direct therapeutic application of native glucagon like peptide-1 is severely limited by its extremely short plasma half-life, primarily resulting from rapid enzymatic degradation by dipeptidyl peptidase-4 & renal clearance. These limitations have necessitated the development of more stable & long-acting glucagon like peptide-1 analogues for clinical use [3].One of the most successful therapeutic classes for the management of type 2 diabetes mellitus & obesity is glucagon like peptide-1 receptor agonists, which were developed overcome the intrinsic limitations of endogenous glucagon like peptide-1. By selectively activating the glucagon like peptide-1 receptor & resisting enzymatic degradation, these agents prolong systemic exposure & enhance therapeutic efficacy [4]. Through strategic structural modifications such as amino acid substitution, lipid conjugation, or fusion carrier molecules, glucagon like peptide-1 RAs achieve sustained glycaemic control with a reduced risk of hypoglycaemia due their glucose-dependent mechanism of action. In addition, improving glycaemic parameters, glucagon like peptide-1 RAs induce clinically significant & durable weight loss, improve cardiometabolic risk profiles, & confer protective effects on cardiovascular & renal outcomes, leading their prioritization in contemporary clinical treatment guidelines for metabolic diseases [5].

The majority of glucagon like peptide-1 receptor agonists are currently administered via subcutaneous injection, which poses a substantial barrier patient acceptance & long-term adherence despite their strong clinical efficacy & favorable safety profile. Injectable therapies are frequently associated with discomfort, needle aversion, inconvenience, & psychological burden, all of which can negatively influence treatment initiation & persistence, particularly in chronic conditions requiring lifelong therapy [6]. Reduced adherence in real-world clinical settings can compromise therapeutic effectiveness & attenuate the long-term benefits observed in controlled clinical trials. Consequently, there has been growing interest in the development of orally administered glucagon like peptide-1 receptor agonist formulations that combine the robust efficacy of this drug class with the convenience, familiarity, & patient preference associated with oral dosage forms [7].Because of the complex & hostile environment of the gastrointestinal tract, oral delivery of peptide-based therapeutics has long been considered extremely challenging. Peptides are intrinsically unstable macromolecules with high hydrophilicity & poor intestinal epithelial permeability, resulting in minimal absorption following oral administration. In addition, the presence of acidic gastric conditions, abundant proteolytic enzymes, & the protective mucus barrier further compromises peptide stability & transport within the gastrointestinal tract [8]. Nevertheless, recent advances in pharmaceutical formulation science, excipient design, & delivery technologies have renewed interest in oral peptide delivery. These developments have challenged long-standing assumptions regarding the feasibility of oral peptide therapeutics by demonstrating that pharmacologically relevant systemic exposure can be achieved for large & structurally complex biomolecules through appropriate formulation strategies & optimized dosing regimens [9].

Despite these advances, the oral administration of glucagon like peptide-1 receptor agonists remains highly challenging. These peptides exhibit poor lipophilicity & relatively high molecular weights (3–4 kDa), which severely restrict passive diffusion across the intestinal epithelial barrier. In addition, glucagon like peptide-1 receptor agonists are highly susceptible degradation by gastric acid & gastrointestinal proteolytic enzymes present in both the stomach & small intestine, while the intestinal mucus layer further limits absorption by trapping peptide molecules & restricting their diffusion ward the epithelial surface [10]. Even when epithelial uptake occurs, extensive first-pass hepatic metabolism markedly reduces the fraction of drug reaching the systemic circulation. Consequently, these combined biological & physiological barriers result in extremely low & highly variable oral bioavailability [11].A wide range of formulation strategies has been investigated overcome the multifactorial barriers associated with the oral delivery of glucagon like peptide-1 receptor agonists. These approaches include molecular modifications enhance peptide stability & membrane interactions, gastroretentive formulations prolong residence time at favorable absorption sites, nanocarrier-based systems protect peptides & facilitate transport, enzyme inhibitors reduce proteolytic degradation, & absorption enhancers transiently increase epithelial permeability [12]. While each strategy offers distinct advantages, they are also associated with limitations related safety, interindividual variability, manufacturing complexity, scalability, & regulatory acceptance.

 

 

 

Fig 1: Oral Delivery of GLP-I Receptor Agonists

 

Consequently, effective oral peptide delivery often requires the integration of multiple complementary technologies rather than reliance on a single formulation intervention, particularly for therapies intended for long-term administration [13].It is imperative critically assess current developments in oral glucagon like peptide-1 receptor agonist delivery given the fast-rising worldwide burden of type 2 diabetes mellitus & obesity, as well as the expanding need for non-injectable biologic medicines [14].  Direct future research & development efforts, a thorough grasp of the biological obstacles, formulation techniques, clinical performance, & translational difficulties are crucial. This kind of assessment is required make sure that new oral glucagon like peptide-1 receptor agonist technologies strike the best possible balance between patient convenience, safety, efficacy, & regulatory viability. Therefore, with a focus on translational relevance & future directions, this review attempts methodically investigate the difficulties related oral delivery of glucagon like peptide-1 receptor agonists & critically discuss established & emerging formulation strategies intended overcome these challenges [15].

2. GLP-1 Receptor Agonists: An Overview

A significant class of incretin-based medications known as glucagon-like peptide-1 receptor agonists imitates the physiological effects of endogenous glucagon like peptide-1 [16]. These medications are very successful in treating type 2 diabetes mellitus (T2DM) & obesity because they increase glucose-dependent insulin secretion, restrict glucagon release, postpone stomach emptying, decrease hunger, & encourage clinically substantial weight loss [17].However, endogenous glucagon like peptide-1 has a very short plasma half-life of less than two minutes due its quick degradation by dipeptidyl peptidase-4 (DPP-4). Synthetic glucagon like peptide-1 receptor agonists have been designed with structural alterations that provide improved stability & extended systemic activity in order get around this restriction [18].

By attaching glucagon like peptide-1 receptors expressed in several tissues, such as the pancreas, gastrointestinal tract, central nervous system, kidney, & cardiovascular system, Glucagon like peptide-1 receptor agonists produce their pharmacological effects. When these receptors are activated, glucagon secretion is suppressed & glucose-dependent insulin secretion is stimulated via cyclic adenosine monophosphate (cAMP)-mediated signalling pathways [19]. Additionally, by acting on cerebral satiety centres, Glucagon like peptide-1 receptor agonists decrease hunger & postpone gastric emptying, which results in lower energy intake & long-term weight loss. Large cardiovascular outcome studies have indicated that these medicines have cardioprotective effects, such as reduced inflammation & enhanced endothelial function, in addition improving β-cell activity & survival. Glucagon like peptide-1 receptor agonists are now considered essential treatments in the treatment of contemporary diabetes due their combined metabolic & cardiovascular advantages [20].Glucagon like peptide-1 receptor agonists are made  withst& enzymatic degradation & prolong their duration of action from a pharmacokinetic & pharmacological st&point.  accomplish this goal, a number of molecular techniques have been used, such as fusion  large carrier proteins like immunoglobulin Fc fragments, amino acid substitutions  provide resistance  dipeptidyl peptidase-4 (DPP-4) cleavage, & fatty acid acylation  encourage reversible albumin binding [21].  further improve molecule stability & systemic exposure, other strategies like PEGylation & peptide backbone modification have also been investigated. Because of these structural changes, elimination half-lives are noticeably longer, which permits fewer doses & better patient convenience. As a result, long-acting glucagon like peptide-1 receptor analogues have half-lives ranging from several days  around one week, allowing for simple once-weekly dosage regimens, while short-acting glucagon like peptide-1 receptor agonists usually require several daily injections [22].

 

 

 

Fig 2: Mechanism of Action Of GLP-I Receptor Agonists

 

Exenatide, liraglutide, dulaglutide, semaglutide, & lixisenatide are among the glucagon like peptide-1 receptor agonists that are presently authorised for clinical usage [23]. A combined glucose-dependent insulinotropic polypeptide (GIP) & glucagon like peptide-1 receptor agonist is another more recent pharmaceutical development that has shown better glycaemic management & improved weight-loss results when compared conventional glucagon like peptide-1 receptor agonists. Because of the differences in these medicines' molecular structures, pharmacokinetic characteristics, & dosage frequency, customised treatment selection based on patient requirements & clinical response is possible [24].The creation of a glucagon like peptide-1 receptor agonist that may be taken orally is one of the most important developments in peptide-based treatments [25]. The integration of an absorption-enhancing excipient system intended shield the peptide from gastrointestinal breakdown & promote epithelial uptake made this accomplishment possible. This strategy's effective clinical translation has encouraged more research in non-injectable biologic medicines & offered proof-of-concept for the oral delivery of complicated peptide medications [26].

Despite their clinical success, glucagon like peptide-1 receptor agonists present substantial challenges for oral delivery. These peptide-based molecules possess relatively high molecular weights in the range of 3–4 kDa, exhibit pronounced hydrophilicity & poor lipophilicity, & are highly susceptible enzymatic degradation in the acidic gastric environment as well as throughout the intestinal tract. Furthermore, their epithelial permeability is extremely low, & they are subject extensive first-pass metabolism, all of which severely limit oral bioavailability [27]. These combined barriers explain why most glucagon like peptide-1 receptor agonists are available exclusively as injectable formulations & why extensive formulation innovation was required achieve clinically viable oral peptide therapies. As a result, oral distribution of glucagon like peptide-1 receptor agonists continues be a significant pharmacological problem & motivates research in sophisticated formulation techniques, such as molecular structural alterations, absorption enhancers, nanocarrier-based systems, & gastroretentive platforms [28].

 

 

 

 

Fig 3: Structural Modifications of GLP-I Receptor Agonists

 

3. Challenges in Oral Delivery of GLP-1 Receptor Agonists

3.1. Overview of Biological & Physiological Barriers Oral GLP-1 Delivery

Glucagon like peptide-1 receptor agonists' biological origin, physicochemical characteristics, & the intricate environment of the gastrointestinal tract present a number of interconnected obstacles for oral delivery [29]. Together, these obstacles lead incredibly poor & highly variable oral bioavailability, which restricts the practical viability of traditional oral dose forms for peptide-based treatments [30].

3.2. Enzymatic Degradation in the Gastrointestinal Tract

Enzymatic breakdown in the gastrointestinal tract is one of the main obstacles the oral administration of glucagon like peptide-1 receptor agonists [31]. Peptide-based compounds known as glucagon like peptide-1 receptor agonists are extremely vulnerable proteolytic enzymes, including trypsin, chymotrypsin, & elastase in the small intestine & pepsin in the stomach. A sizable portion of the given dose experiences quick enzymatic cleavage even before it reaches the absorptive epithelium, which results in a loss of biological activity. A significant barrier obtaining therapeutically relevant plasma concentrations after oral treatment is this widespread presystemic breakdown [32].

3.3. Acidic Gastric pH–Induced Instability

Peptide integrity is further jeopardised by acidic stomach pH in addition enzymatic nstability [33]. Peptide denaturation, aggregation, & hydrolysis can be caused by the harsh stomach environment, which has a pH range of roughly 1–3. This is especially true for structurally complicated compounds like glucagon like peptide-1 receptor agonists. Delayed drug release frequently moves the site of exposure the colon, where significant enzymatic breakdown continues, even if enteric coating techniques may offer some protection against gastric acidity. Therefore, pH-related instability continues be a major obstacle the effective oral administration of peptide-based treatments [34].

3.4. Poor Intestinal Epithelial Permeability

Poor epithelium permeability is another significant barrier the oral administration of glucagon like peptide-1 receptor agonists [35]. Glucagon like peptide-1 receptor agonists have very little passive diffusion through the intestinal epithelium because of their high molecular weight (around 3–4 kDa), strong hydrophilicity, & several hydrogen-bond-forming functional groups. While transcellular transport is limited by low lipophilicity & the lack of particular transport mechanisms, paracellular transport is severely restricted by tight junctions between epithelial cells. As a result, glucagon like peptide-1 receptor agonists' effective permeability coefficients are insufficient enable significant systemic absorption after oral treatment [36].

3.5. Mucus Barrier–Mediated Limitation of Drug Transport

Another physiological barrier the oral administration of glucagon like peptide-1 receptor agonists is the mucus barrier. Large, hydrophilic molecules are trapped by the intestinal mucus layer, which acts as a viscoelastic gel restrict their diffusion wards the epithelial surface [37]. Before reaching absorptive cells, peptide therapies like glucagon like peptide-1 receptor agonists may become stuck or degrade in the mucus layer, further decreasing oral bioavailability. Furthermore, variations in systemic exposure & irregular absorption patterns can be caused by interindividual differences in mucus composition & thickness [38].

3.6. First-Pass Metabolism & Hepatic Clearance

Moreover, even with effective epithelial absorption, first-pass metabolism dramatically lowers systemic exposure. The portal circulation carries peptides that have been absorbed via the intestinal epithelium the liver, where they may undergo further metabolic breakdown prior entering the systemic circulation. The extremely low absolute bioavailability of oral glucagon like peptide-1 receptor agonists, which usually stays below 1% in the absence of specialised delivery technology, is further exacerbated by this occurrence [39].

3.7. Patient-Related & Physiological Variability Affecting Oral Absorption

Glucagon like peptide-1 receptor agonist oral delivery results are also significantly influenced by physiological & patient-related factors. Drug absorption & systemic exposure can be significantly impacted by gastrointestinal transit time, the presence or absence of food, variations in stomach emptying, & interindividual variations in digestive enzyme expression & epithelium integrity [40]. For instance, reduce pharmacokinetic variability & improve absorption, oral glucagon like peptide-1 receptor agonist formulations frequently need be delivered under tightly regulated circumstances, such as while fasting & with a small amount of water. These specifications draw attention the practical & patient-related difficulties that oral peptide treatment presents in actual clinical settings [41].

 

 

 

 

 

 

 

 

 

 

Table No 1: Physicochemical & Biological Barriers to Oral Delivery of GLP-1 RAs

 

 

 

Sr. No.

Barrier Category

Specific Barrier

Impact on Oral Bioavailability

Reference

1

Enzymatic

Pepsin, trypsin, chymotrypsin

Rapid peptide degradation

[42]

2

pH-related

Gastric acidity (pH 1–3)

Denaturation & hydrolysis

[43]

3

Physicochemical

High MW (3–4 kDa), hydrophilicity

Poor membrane permeability

[44]

4

Epithelial

Tight junction restriction

Limited paracellular transport

[45]

5

Mucus

Mucus entrapment

Reduced epithelial access

[46]

6

Metabolic

First-pass hepatic metabolism

Reduced systemic exposure

[47]

7

Physiological

Food effect, GI transit variability

High PK variability

[48]

 

3.8. Implications for the Need of Advanced Oral Delivery Strategies

Together, these physiological, physicochemical, & biological limitations highlight the need for sophisticated formulation techniques & explain why the majority of glucagon like peptide-1 receptor agonists are currently injected. Innovative strategies, such as absorption enhancers, enzyme inhibitors, nanocarrier-based systems, gastroretentive formulations, & peptide structural modifications—all of which are covered in depth in later sections of this review—are needed overcome these obstacles [49].

4. Formulation Strategies for Oral Delivery of GLP-1 Receptor Agonists:

4. 1. Rationale & Overview of Advanced Oral Formulation Approaches

Numerous formulation techniques have been studied get over the many biological & physicochemical obstacles related the oral administration of glucagon like peptide-1 receptor agonists. These methods are intended lengthen gastrointestinal residence time, improve epithelial permeability, shield peptide molecules from chemical & enzymatic destruction, & ultimately increase systemic bioavailability [50]. Successful oral delivery frequently necessitates the integration of several complimentary technologies rather than relying on a single formulation intervention due the inherent complexity of peptide-based medicines [51].

4. 2. Absorption Enhancers: Clinical Success & Limitations of SNAC-Based Systems

The use of absorption enhancers, which momentarily improve intestinal permeability & promote transcellular or paracellular transport of peptide molecules, is one of the most therapeutically sophisticated formulation techniques for oral delivery of glucagon like peptide-1 receptor agonists. Due its successful use in an oral glucagon like peptide-1 receptor agonist formulation, sodium N- [8-(2-hydroxy benzoyl) amino] caprylate (SNAC) has drawn a lot of attention among these. According reports, SNAC works by promoting transcellular absorption across the gastric epithelium, increasing the apparent lipophilicity of the peptide, & locally raising the pH of the stomach lessen acid-mediated peptide breakdown [52]. Even though the absolute oral bioavailability is usually less than 1%, this multifactorial approach allows for measurable systemic exposure. However, the need for relatively high SNAC concentrations & stringent fasting conditions draws attention significant drawbacks, such as absorption variability & possible safety issues with long-term permeation enhancer usage [53].

 

 

 

Fig 4: SNAC-Based Absorption Mechanism for Oral Semaglutide

 

4. 3. Alternative Absorption Enhancers & Permeation-Modulating Agents

Other kinds of absorption enhancers, such as medium-chain fatty acids, bile salt derivatives, chelating agents like ethylenediaminetetraacetic acid (EDTA), & surfactants, have been thoroughly studied for oral peptide administration in addition SNAC. Through processes like temporary relaxation of tight junctions, enhanced membrane fluidity, & modification of transporter or efflux activity, these drugs improve peptide absorption [54]. Concerns about epithelial damage, long-term safety, & high interindividual variability in absorption have hindered the clinical translation of such strategies, especially for chronic therapies like glucagon like peptide-1 receptor agonists, even though they have shown notable improvements in peptide permeability in preclinical models [55].

4. 4. Enzyme Inhibition Strategies to Reduce Gastrointestinal Proteolysis

Incorporating enzyme inhibitors lessen proteolytic breakdown in the gastrointestinal system is another crucial formulation technique. It has been demonstrated that protease inhibitors, such as pepstatin A, soybean trypsin inhibitor, & aprotinin, shield peptide medicines from enzymatic cleavage & improve oral bioavailability [56]. Chronic suppression of digestive enzymes, however, raises questions about possible immunogenicity, gastrointestinal damage, & poor nutritional absorption. For the oral delivery of glucagon like peptide-1 receptor agonists, enzyme inhibitors are therefore typically considered supplementary formulation components rather than standalone treatments [57].

4. 5. Nanotechnology-Based Delivery Systems for Enhanced Stability & Permeability

A promising platform for the oral administration of peptide therapies is nanotechnology-based delivery systems. glucagon like peptide-1 receptor agonists can be encapsulated by polymeric nanoparticles, lipid-based carriers, & hybrid delivery methods, preserving them from enzymatic degradation & promoting transport across the intestinal epithelium. Because of their biocompatibility, biodegradability, & adjustable drug release characteristics, polymers including poly (lactic-co-glycolic acid) (PLGA), chitosan, & Eudragit have been thoroughly studied [58]. Particularly, chitosan-based nanoparticles have significant mucoadhesive properties & can temporarily open epithelial tight junctions, improving peptide medication paracellular delivery. Furthermore, lipid-based nanocarriers such solid lipid nanoparticles & nanostructured lipid carriers may enhance systemic exposure & decrease first-pass hepatic metabolism by promoting lymphatic absorption & improving peptide stability [59].

4. 6. Gastroretentive Delivery Systems for Prolonged Gastric Exposure

Another significant formulation strategy that is especially pertinent glucagon like peptide-1 receptor agonists is gastroretentive delivery methods, particularly for oral formulations that show preferential absorption in the stomach. The purpose of dosage forms such mucoadhesive formulations, expandable systems, & floating tablets is increasing the length of drug exposure at the absorption site by extending the gastric residence time [60]. These devices can increase the possibility of peptide absorption while lowering exposure intestinal proteolytic enzymes by keeping prolonged contact with the stomach mucosa. However, obtaining consistent & predictable performance of gastroretentive systems continues be significantly hampered by variations in stomach motility, gastric emptying rates, & patient-dependent physiological parameters [61].

4. 7. Combination & Multifunctional Formulation Strategies

For the oral administration of peptide therapies, combination approaches that incorporate several protective & permeation-enhancing mechanisms are being investigated more & more. These methods include combinations of enteric coatings, pH-modifying excipients, or nanoparticulate carrier systems with absorption enhancers [62]. These multipurpose delivery systems are intended  minimise the safety hazards connected with the use of large quantities of specific excipients while simultaneously achieving synergistic increases in peptide stability & epithelial permeability. Because it allows for a balanced optimisation of efficacy, safety, & translational potential, this integrated formulation technique is becoming more & more popular in the development of next-generation oral peptide therapies [63].

4. 8. Emerging & Device-Assisted Oral Delivery Technologies

For peptide therapies, a number of innovative oral administration methods are now being researched in addition traditional formulations. Increase oral peptide uptake & stability inside the gastrointestinal tract, proprietary carrier-based absorption platforms & protein oral delivery systems use optimised combinations of permeation enhancers & protective matrices [64]. Although these technologies have great potential improve oral bioavailability, significant concerns regarding scalability, manufacturing complexity, cost-effectiveness, & long-term safety must be carefully evaluated before they can be widely applied in clinical settings [65].

4. 9. Current Status & Future Perspectives in Oral GLP-1 Formulation Development

 

 

 

 

 

 

 

 

 

 

 

 

As demonstrated by the successful commercialisation of an oral glucagon like peptide-1 receptor agonist, formulation techniques for the oral delivery of glucagon like peptide-1 receptor agonists have generally advanced significantly. However, limited absolute bioavailability, stringent dosage requirements, & persistent safety concerns related long-term administration continue limit current methods [66]. Future development & wider clinical use of oral glucagon like peptide-1 receptor agonists will depend on ongoing innovation centred on the creation of safer permeation-enhancing technology, enhanced peptide stability, & more patient-friendly dosage regimes [67].

 

Table No 2: Formulation Strategies for Oral GLP-1 Receptor Agonists

 

Sr. No.

Strategy

Mechanism

Advantages

Limitations

Reference

1

Absorption enhancers (SNAC)

↑ Transcellular transport

Clinically validated

Low bioavailability, fasting required

[68]

2

Enzyme inhibitors

Protease inhibition

Protect peptide

Safety concerns

[69]

3

Nanoparticles

Encapsulation & protection

Enhanced stability

Scale-up challenges

[70]

4

Gastroretentive systems

Prolong gastric residence

Site-specific absorption

GI variability

[71]

5

Mucoadhesive systems

Increased contact time

Improved uptake

Mucus trapping risk

[72]

6

Combination systems

Synergetic effects

Higher efficiency

Formulation complexity

[73]
 

5. Clinically Advanced Oral GLP-1 Receptor Agonist Formulations

5. 1. Clinical Translation & Proof-of-Concept for Oral Peptide Delivery

An important development in the realm of peptide medication delivery is the effective clinical translation of oral glucagon like peptide-1 receptor agonists. Orally administered glucagon like peptide-1 receptor agonists, in contrast traditional injectable formulations, necessitate extremely complex formulation techniques get over substantial first-pass metabolism, low epithelial permeability, & gastrointestinal degradation [74]. Recent developments have shown that clinically significant therapeutic effects can be attained through optimised formulation design in conjunction with meticulously regulated dosage methods, even while absolute oral bioavailability is still low [75].

5. 2. Multifunctional Excipient Systems for Protection & Absorption Enhancement

Clinically sophisticated oral glucagon like peptide-1 receptor agonist formulations usually rely on multifunctional excipient systems that improve epithelium absorption while simultaneously shielding peptide molecules from enzymatic & acidic breakdown. These systems frequently use transcellular transport channels, temporary changes in membrane fluidity, & localised manipulation of stomach pH [76]. Even while absolute bioavailability levels often stay below 1%, these formulations offer systemic exposure sufficient elicit pharmacodynamic effects comparable parenteral delivery by fostering a favourable milieu that improves peptide stability & absorption [77].

5. 3. Formulation-Assisted Site-Specific Absorption Strategies

Site-specific absorption is another distinguishing feature of sophisticated oral glucagon like peptide-1 receptor agonist formulations. Some formulations are specifically made encourage absorption in the upper gastrointestinal tract, where residence time can be more effectively controlled & enzymatic exposure may be relatively reduced, as opposed primarily depending on intestinal uptake, which is linked extensive enzymatic activity & restrictive epithelial barriers [78]. This approach emphasises how crucial it is targeting particular gastrointestinal areas with formulation assistance in order improve systemic exposure & oral peptide absorption [79].

5. 4. Clinical Efficacy & Dependence on Controlled Dosing Conditions

Glycated haemoglobin (HbA1c) levels & body weight have consistently decreased in clinical trials of oral glucagon like peptide-1 receptor agonists, demonstrating that oral administration can achieve therapeutic efficacy when accompanied by suitable formulation technologies. Strict dosing guidelines, such as administering the medication when fasting & limiting water & post-dose food intake, are crucial for these clinical results [80]. In order produce oral peptide medicines that are both successful & patient-friendly, it is necessary strike a careful balance between formulation performance & patient convenience [81].

5. 5. Limitations, Variability, & Safety Considerations in Clinical Use

Despite these developments, oral glucagon like peptide-1 receptor agonist formulations with clinical validation continue have a number of significant drawbacks. Significant obstacles still include the need for comparatively high quantities of functional excipients, notable interindividual variability in absorption, & sensitivity gastrointestinal physiological circumstances [82]. Furthermore, rigorous regulatory assessment & post-marketing surveillance are required due long-term safety concerns associated with chronic exposure permeation-enhancing excipients. When taken as a whole, these elements highlight the necessity of ongoing innovation targeted at increasing patient adherence oral peptide therapy, lowering dosage restrictions, & strengthening formulation robustness [83].

5. 6. Impact on the Future of Oral Biologic & Peptide Therapeutics

All things considered, the clinical success of sophisticated oral glucagon like peptide-1 receptor agonist formulations has shown strong evidence that oral peptide delivery is feasible. Expectations for non-injectable biologic medicines have changed as a result of these advancements, which have also sparked larger research initiatives apply comparable formulation techniques additional therapeutic peptides [84]. Crucially, the rational design of next-generation oral delivery systems with better safety profiles, increased therapeutic efficacy, & higher patient acceptance is still influenced by the lessons discovered throughout the development & clinical translation of existing formulations [85].

6. Emerging Technologies for Oral Delivery of GLP-1 Receptor Agonists

 Conventional formulation methods for oral glucagon like peptide-1 receptor agonist delivery are still limited by low absolute bioavailability, stringent dosage requirements, & safety issues related  long-term exposure  permeation-enhancing excipients, despite recent clinical advancements. As a result, a variety of cutting-edge methods are being actively investigated  enhance the oral administration of glucagon like peptide-1 receptor agonists. While preserving long-term safety & lerability, these next-generation approaches seek  improve peptide stability, boost epithelial transport efficiency, decrease interindividual variability in drug absorption, & promote patient comfort [86].Peptide structure engineering is one exciting field of study for oral glucagon like peptide-1 receptor agonist administration. It has been demonstrated that rational peptide sequence modification, including amino acid replacement, cyclisation, lipid conjugation, & backbone stabilisation, can increase resistance enzyme degradation while maintaining receptor affinity & biological activity [87]. Fatty-acid conjugation is one of these tactics that works well because it increases reversible albumin binding & lengthens the duration of systemic circulation, which helps partially offset oral absorption. These molecular optimisation techniques serve as a useful supplement formulation-based distribution methods & lessen reliance on strong permeation enhancers [88].Recently, deep eutectic systems & ionic liquids have drawn more interest as innovative excipient platforms for oral peptide administration. By creating short-lived, non-covalent complexes with the therapeutic molecule, these systems can improve membrane permeability, physicochemical stability, & peptide solubility [89]. Additionally, by modifying membrane fluidity & decreasing peptide aggregation at the epithelial interface, ionic liquid-based formulations may promote transcellular transport. Even though these methods are still in the early stages of development, they offer a flexible & adjustable way enhance oral peptide absorption & show promise for oral biologic formulations of the future [90].Another significant new trend in oral peptide delivery is the development of muco-penetrating & mucus-modulating delivery devices. Muco-penetrating nanoparticles are specifically designed quickly diffuse through mucus & reach the epithelial surface, in contrast conventional mucoadhesive formulations that increase gastrointestinal residence duration but may retain peptides within the mucus layer. Surface modification with hydrophilic polymers, like polyethylene glycol, improves epithelial access & decreases sticky interactions with mucus components. In preclinical research, these systems have shown increased absorption consistency & decreased interindividual variability, underscoring their potential improve oral peptide delivery reliability [91].In order provide site-specific & regulated release of peptide therapies after oral administration, stimuli-responsive delivery devices are also being actively investigated. In order start drug release at the best absorption locations, these systems are made react physiological triggers such changes in pH, enzyme activity, or redox conditions within the gastrointestinal tract [92]. Stimuli-responsive formulations can improve absorption efficiency while reducing premature breakdown in harsh gastrointestinal environments by coordinating peptide release with advantageous local physiological conditions. These intelligent delivery methods are a major step wards precision oral peptide therapy & have great potential increase the efficacy & dependability of biologics taken orally [93].Device-assisted oral administration systems that physically get beyond restrictions on epithelial permeability are among the more revolutionary strategies. Early-stage research has shown encouraging results for ingestible devices that may orient themselves within the gastrointestinal tract & deliver peptide therapies straight across the mucosal barrier. These methods provide the possibility of greater & more reliable systemic bioavailability by doing away with the need for chemical permeation enhancement or passive diffusion. Widespread clinical adoption is still hampered by serious issues with patient acceptance, cost-effectiveness, manufacturing scalability, & device complexity [94].Lastly, AI-assisted formulation design & computer modelling are becoming effective methods for improving oral peptide delivery systems. Key factors including peptide stability, epithelial permeability, & drug–excipient interactions can be predicted by machine learning & data-driven models, which speeds up formulation development & lessens the need for experimental trial-&-error methods [95]. Future oral glucagon like peptide-1 receptor agonist formulations is anticipated be rationally designed & optimised through the integration of in silico modelling with experimental & clinical data, allowing for more effective, reliable, & patient-centered delivery methods [96].

7. Regulatory & Quality Considerations for Oral GLUCAGON LIKE PEPTIDE-1 Receptor Agonist Formulations

Because of their peptide composition, intricate formulation techniques, & dependence on absorption-enhancing technologies, the development of oral glucagon like peptide-1 receptor agonists poses particular regulatory & quality problems. Regulatory bodies, including significant international organisations, demand a thorough assessment of these products' safety, effectiveness, & quality characteristics, going above & beyond what is usually required for traditional small-molecule oral medications [97]. Because oral peptide therapies are more complex, special attention is paid the safety of novel excipients, long-term exposure permeation enhancers, formulation resilience, & consistency of clinical performance [98].

The safety of excipients & permeation enhancers used increase oral absorption is a key regulatory concern in the development of orally administered glucagon like peptide-1 receptor agonists. Regulatory bodies need thorough explanations of the mechanism of action, reversibility, & long-term safety of oral glucagon like peptide-1 receptor agonist formulations since many of them rely on excipients that momentarily change membrane permeability or epithelial integrity [99]. Long-term clinical safety studies & comprehensive non-clinical toxicology evaluations are required support regulatory approval of such excipients due concerns about epithelial damage, local inflammation, & possible changes in gastrointestinal function [100].Glucagon like peptide-1 receptor agonists & other oral peptide formulations should be developed using Quality-by-Design (QbD) principles. Peptide integrity, impurity profile, stability under gastrointestinal circumstances, & batch-batch uniformity are examples of critical quality qualities that need be precisely defined & strictly regulated. Regulatory bodies place special emphasis on thorough knowledge & control of degradation pathways like hydrolysis, oxidation, aggregation, & enzymatic cleavage throughout the whole product lifecycle, from manufacture clinical use, because peptide therapeutics are inherently physicochemically unstable [101].Pharmacokinetic variability is a significant regulatory problem for oral glucagon like peptide-1 receptor agonist formulations from the standpoint of bioavailability. Due variations in gastrointestinal physiology, stomach emptying rates, digestive enzyme activity, & patient adherence particular dosage circumstances, these products often show substantial inter- & intra-subject variability. Therefore, in order ensure dependable clinical performance, regulatory authorities require well-designed clinical pharmacokinetic & pharmacodynamic studies show consistent exposure–response relationships & justify dosing instructions, including fasting requirements & food & water intake restrictions [102].Immunogenicity testing is another crucial regulatory factor in the creation of oral glucagon like peptide-1 receptor agonists. Despite the fact that glucagon like peptide-1 receptor agonists typically have a low intrinsic immunogenic potential, oral administration may pose extra dangers because of partial peptide degradation, chemical modification, or the creation of new peptide-related contaminants. In order guarantee long-term safety & identify any clinically significant immune reactions connected long-term oral administration, regulatory rules require thorough immunogenicity investigation throughout clinical development as well as ongoing post-marketing surveillance [103].

CONCLUSION

Glucagon like peptide-1 receptor agonist oral administration is a significant advancement in peptide-based treatments, providing a patient-friendly substitute for injectable formulations & resolving persistent adherence issues. Recent developments have shown that clinically significant therapeutic efficacy can be attained through logical formulation design & optimised dosing strategies, even with low absolute oral bioavailability, despite significant biological & physicochemical barriers, such as enzymatic degradation, poor epithelial permeability, mucus entrapment, & extensive first-pass metabolism. Successful oral administration has been made possible by advances in formulation science, particularly the use of absorption enhancers, multifunctional excipient systems, nanotechnology-based carriers, & gastroretentive techniques.However, stringent dosage guidelines, interindividual pharmacokinetic variability, & safety concerns over long-term exposure permeation-enhancing excipients continue restrict currently authorised formulations. Peptide structural engineering, muco-penetrating systems, stimuli-responsive platforms, device-assisted delivery, & artificial intelligence-guided formulation design are examples of emerging technologies that are anticipated further progress the field wards oral peptide therapies that are safer, more reliable, & patient-centered.From a regulatory standpoint, early regulatory involvement, thorough safety review, & strict application of Quality-by-Design principles are necessary for successful development. All things considered, the advancements made with oral Glucagon like peptide-1 receptor agonists will probably influence the creation of non-injectable biologics in the future & alter expectations regarding the oral administration of complex peptide treatments.

REFERENCES

  1. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Molecular metabolism. 2022 Mar 1;57:1-13.

https://doi.org/10.1016/j.molmet.2021.101351

  1. Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ. Glucagon-like peptide 1 (GLP-1). Molecular metabolism. 2019 Dec 1;30:72-130.

https://doi.org/10.1016/j.molmet.2019.09.010

  1. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Molecular metabolism. 2021 Apr 1;46:1-26. https://doi.org/10.1016/j.molmet.2020.101102
  2. Klen J, Dolžan V. Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus & obesity: the impact of pharmacological properties & genetic factors. International journal of molecular sciences. 2022 Mar 22;23(7):1-18.

https://doi.org/10.3390/ijms23073451

  1. Helmstädter J, Keppeler K, Küster L, Münzel T, Daiber A, Steven S. Glucagon?like peptide?1 (GLP?1) receptor agonists & their cardiovascular benefits—The role of the GLP?1 receptor. British journal of pharmacology. 2022 Feb;179(4):659-676.  

https://doi.org/10.1111/bph.15462

  1. Myers JT, Dam JV, Imran M, Hashim M, Dhalla AK. Preference for a novel oral alternative to parenterally administered medications. Patient preference & adherence. 2024 Dec 31:1547-1562.

https://doi.org/10.2147/PPA.S463354

  1. Matza LS, Cutts KN, Stewart KD, Norrbacka K, García-Pérez LE, Boye KS. Health state utilities associated with treatment process for oral & injectable GLP-1 receptor agonists for type 2 diabetes. Quality of Life Research. 2021 Jul;30(7):2033-2043.

https://doi.org/10.1007/s11136-021-02808-2

  1. Zhang Y, Zhang H, Ghosh D, Williams III RO. Just how prevalent are peptide therapeutic products? A critical review. International journal of pharmaceutics. 2020 Sep 25;587:1-47. https://doi.org/10.1016/j.ijpharm.2020.119491
  2. Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W, Hu Y, Shi J. Advance in peptide-based drug development: delivery platforms, therapeutics & vaccines. Signal Transduction & Targeted Therapy. 2025 Mar 5;10(1):1-56.

https://doi.org/10.1038/s41392-024-02107-5

  1. Baral KC, Choi KY. Barriers & strategies for oral peptide & protein therapeutics delivery: update on clinical advances. Pharmaceutics. 2025 Mar 21;17(4):1-30. https://doi.org/10.3390/pharmaceutics17040397
  2. Yang X, Lin R, Feng C, Kang Q, Yu P, Deng Y, Jin Y. Research Progress on Peptide Drugs for Type 2 Diabetes & the Possibility of Oral Administration. Pharmaceutics. 2024 Oct 23;16(11):1-24.

https://doi.org/10.3390/pharmaceutics16111353

  1. McBrayer DN, Tal?Gan Y. Recent advances in GLP?1 receptor agonists for use in diabetes mellitus. Drug development research. 2017 Sep;78(6):292-309.

 https://doi.org/10.1002/ddr.21404

  1. Gleeson JP, Fein KC, Whitehead KA. Oral delivery of peptide therapeutics in infants: Challenges & opportunities. Advanced drug delivery reviews. 2021 Mar 25;173:1-29.

10.1016/j.addr.2021.03.011

  1. Wu T, Wong CK, Lui DT, Wong SK, Lam CL, Chung MS, McAllister DA, Welbourn R, Dixon JB. Bariatric surgery, novel glucose-lowering agents, & insulin for type 2 diabetes & obesity: Bayesian network meta-analysis of randomized controlled trials. BJS open. 2023 Aug;7(4):1-11.

https://doi.org/10.1093/bjsopen/zrad077

  1. Pechenov S, Revell J, Will S, Naylor J, Tyagi P, Patel C, Liang L, Tseng L, Huang Y, Rosenbaum AI, Balic K. Development of an orally delivered GLP-1 receptor agonist through peptide engineering & drug delivery to treat chronic disease. Scientific Reports. 2021 Nov 18;11(1):1-15.

https://doi.org/10.1038/s41598-021-01750-0

  1. Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y. GLP-1 receptor agonists: beyond their pancreatic effects. Frontiers in endocrinology. 2021 Aug 23;12:1-19.  https://doi.org/10.3389/fendo.2021.721135
  2. Borner T, Tinsley IC, Doyle RP, Hayes MR, De Jonghe BC. Glucagon?like peptide?1 in diabetes care: Can glycaemic control be achieved without nausea & vomiting?. British journal of pharmacology. 2022 Feb;179(4):542-556.

https://doi.org/10.1111/bph.15647

  1. Kuthati Y, Davuluri VN, Wong CS. Therapeutic effects of GLP-1 receptor agonists & DPP-4 inhibitors in neuropathic pain: mechanisms & clinical implications. Biomolecules. 2025 Apr 26;15(5):1-17. 

https://doi.org/10.3390/biom15050622

  1. Danowitz M, De Leon DD. The role of GLP-1 signaling in hypoglycemia due to hyperinsulinism. Frontiers in Endocrinology. 2022 Mar 24;13:1-7.  

https://doi.org/10.3389/fendo.2022.863184

  1. Qin J, Song L. Glucagon-like peptide-1 (GLP-1) receptor agonists & cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials. BMC endocrine disorders. 2022 May 12;22(1):1-7.  

10.1186/s12902-022-01036-0

  1. Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB, Bae SK. A Comprehensive Review on the Pharmacokinetics & Drug− Drug Interactions of Approved GLP-1 Receptor Agonists & a Dual GLP-1/GIP Receptor Agonist. Drug Design, Development & Therapy. 2025 Dec 31:3509-3537. 

https://doi.org/10.2147/DDDT.S506957

  1. Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC & the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in Endocrine & Metabolic Disorders. 2022 Oct;23(5):979-994. 

https://doi.org/10.1007/s11154-022-09735-8

  1. Ryan D, Acosta A. GLP?1 receptor agonists: Nonglycemic clinical effects in weight loss & beyond. Obesity. 2015 Jun;23(6):1119-1129.  

10.1002/oby.21107

  1. Johnson H, Huang D, Liu V, Ammouri MA, Jacobs C, El-Osta A. Impact of digital engagement on weight loss outcomes in obesity management among individuals using GLP-1 & dual GLP-1/GIP receptor agonist therapy: retrospective cohort service evaluation study. Journal of Medical Internet Research. 2025 Mar 31;27:1-18.

10.2196/69466

  1. Antza C, Nirantharakumar K, Doundoulakis I, Tahrani AA, Toulis KA. The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date. Drug design, development & therapy. 2019 Aug 22:2985-2996. 

https://doi.org/10.2147/DDDT.S166765

  1. Maher S, Ryan B, Duffy A, Brayden DJ. Formulation strategies to improve oral peptide delivery. Pharmaceutical patent analyst. 2014 May 1;3(3):313-336.   

https://doi.org/10.4155/ppa.14.15

  1. Liu M, Svirskis D, Proft T, Loh J, Yin N, Li H, Li D, Zhou Y, Chen S, Song L, Chen G. Progress in peptide & protein therapeutics: Challenges & strategies. Acta Pharmaceutica Sinica B. 2025 Oct 25.1-40 

https://doi.org/10.1016/j.apsb.2025.10.026

  1. Richard J. Challenges in oral peptide delivery: lessons learnt from the clinic & future prospects. Therapeutic Delivery. 2017 Jul 1;8(8):663-84.  https://doi.org/10.4155/tde-2017-0024
  2. Choe HJ, Cho YM. Peptidyl & non-peptidyl oral glucagon-like peptide-1 receptor agonists. Endocrinology & Metabolism. 2021 Feb 24;36(1):22-29.   https://doi.org/10.3803/EnM.2021.102
  3. Mehrotra S, Bg PK, Nayak PG, Joseph A, Manikkath J. Recent progress in the oral delivery of therapeutic peptides & proteins: overview of pharmaceutical strategies to overcome absorption hurdles. Advanced Pharmaceutical Bulletin. 2023 Aug 26;14(1):11-33.     

10.34172/apb.2024.009

  1. Liu K, Huang Y, Wang T, Mu R, Rosenbaum AI. In-vitro metabolite identification for MEDI7219, an oral GLP-1 analog, using LC-MS/MS with CID & EAD approaches. Bioanalysis. 2025 Jul 3;17(13):881-888.  

https://doi.org/10.1080/17576180.2025.2535954

  1. Patel S, Vyas VK, Mehta PJ. A review on forced degradation strategies to establish the stability of therapeutic peptide formulations. International Journal of Peptide Research & Therapeutics. 2023 Feb 13;29(2):1-22.  https://doi.org/10.1007/s10989-023-10492-8
  2. Verma S, Go& UK, Husain A, Katekar RA, Garg R, Gayen JR. Challenges of peptide & protein drug delivery by oral route: Current strategies to improve the bioavailability. Drug development research. 2021 Nov;82(7):927-944.  

https://doi.org/10.1002/ddr.21832

  1. Bardonnet PL, Niu Z, Pessi J, Kazakou M, Raptis K, McCabe R, Toftlev A, Rebollo R, Wang Z, Fan L, Mortensen NR. An effort to enhance the clinical translatability of caprate-based tablet formulations in gastric peptide delivery. Drug Delivery & Translational Research. 2025 Sep 23:1-4.  

https://doi.org/10.1007/s13346-025-01978-7

  1. Rocho? J, Kalinowski P, Szymanek-Majchrzak K, Gr?t M. Role of gut-liver axis & glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease. World Journal of Gastroenterology. 2024 Jun 21;30(23):2964-2980.                 

10.3748/wjg.v30.i23.2964

  1. Komin A, Bogorad MI, Lin R, Cui H, Searson PC, Hristova K. A peptide for transcellular cargo delivery: Structure-function relationship & mechanism of action. Journal of Controlled Release. 2020 Aug 10;324:633-643.               

https://doi.org/10.1016/j.jconrel.2020.05.030

  1. Leal J, Dong T, Taylor A, Siegrist E, Gao F, Smyth HD, Ghosh D. Mucus-penetrating phage-displayed peptides for improved transport across a mucus-like model. International journal of pharmaceutics. 2018 Dec 20;553(1-2):57-64. 

https://doi.org/10.1016/j.ijpharm.2018.09.055

  1. Boegh M, Nielsen HM. Mucus as a barrier to drug delivery–understanding & mimicking the barrier properties. Basic & clinical pharmacology & toxicology. 2015 Mar;116(3):179-86.             https://doi.org/10.1111/bcpt.12342
  2. Asano D, Takakusa H, Nakai D. Oral absorption of middle-to-large molecules & its improvement, with a focus on new modality drugs. Pharmaceutics. 2023 Dec 28;16(1):1-27. https://doi.org/10.3390/pharmaceutics16010047
  3. Amigo L, Hernández-Ledesma B. Current evidence on the bioavailability of food bioactive peptides. Molecules. 2020 Sep 29;25(19):1-36.  

https://doi.org/10.3390/molecules25194479

  1. Khan TT, Sheikh Z, Maleknia S, Oveissi F, Fathi A, Abrams T, Ong HX, Traini D. Intranasal delivery of glucagon-like peptide-1 to the brain for obesity treatment: opportunities & challenges. Expert Opinion on Drug Delivery. 2024 Jul 2;21(7):1081-101.  https://doi.org/10.1080/17425247.2024.2387110
  2. Janssen G, Christis C, Kooy-Winkelaar Y, Edens L, Smith D, van Veelen P, Koning F. Ineffective degradation of immunogenic gluten epitopes by currently available digestive enzyme supplements. PloS one. 2015 Jun 1;10(6):1-15. 

https://doi.org/10.1371/journal.pone.0128065

  1. Zapadka KL, Becher FJ, Gomes dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface focus. 2017 Dec 6;7(6):1-18.  https://doi.org/10.1098/rsfs.2017.0030
  2. Kadel S, Pellerin G, Thibodeau J, Perreault V, Lainé C, Bazinet L. How molecular weight cut-offs & physicochemical properties of polyether sulfone membranes affect peptide migration & selectivity during electrodialysis with filtration membranes. Membranes. 2019 Nov 13;9(11):1-18. 

https://doi.org/10.3390/membranes9110153

  1. Roxas JL, Viswanathan VK. Modulation of intestinal paracellular transport by bacterial pathogens. Comprehensive Physiology. 2018 Apr 17;8(2):823-842.  

https://doi.org/10.1002/j.2040-4603.2018.tb00025.x

  1. Wang CM, Fernez MT, Woolston BM, Carrier RL. Native gastrointestinal mucus: Critical features & techniques for studying interactions with drugs, drug carriers, & bacteria. Advanced drug delivery reviews. 2023 Sep 1;200:1-34.

 https://doi.org/10.1016/j.addr.2023.114966

  1. Larder CE, Iskandar MM, Kubow S. Assessment of bioavailability after in vitro digestion & first pass metabolism of bioactive peptides from collagen hydrolysates. Current Issues in Molecular Biology. 2021 Oct 13;43(3):1592-605. 

https://doi.org/10.3390/cimb43030113

  1. Chakrabarti S, Guha S, Majumder K. Food-derived bioactive peptides in human health: Challenges & opportunities. Nutrients. 2018 Nov 12;10(11):1-17.                                      https://doi.org/10.3390/nu10111738
  2. Xu Y, Drucker DJ, Traverso G, Beloqui A. Innovative molecules & delivery technologies enabling the future of GLP-1-based therapies. Endocrine reviews. 2026 Feb;47(1):1-23.   https://doi.org/10.1210/endrev/bnaf027
  3. Drucker DJ. Advances in oral peptide therapeutics. Nature reviews Drug discovery. 2020 Apr;19(4):277-289.    

https://doi.org/10.1038/s41573-019-0053-0

  1. Nicze M, Borówka M, Dec A, Niemiec A, Bu?dak ?, Okopie? B. The current & promising oral delivery methods for protein-& peptide-based drugs. International Journal of Molecular Sciences. 2024 Jan 9;25(2):1-29.  

https://doi.org/10.3390/ijms25020815

  1. Solis-Herrera C, Kane MP, Triplitt C. Current understanding of sodium n-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: The oral semaglutide experience. Clinical Diabetes. 2024 Jan 1;42(1):74-86. 

https://doi.org/10.2337/cd22-0118

  1. Tran H, ElSayed ME. Progress & limitations of oral peptide delivery as a potentially transformative therapy. Expert Opinion on Drug Delivery. 2022 Feb 1;19(2):163-178.

https://doi.org/10.1080/17425247.2022.2051476

  1. Salehi T, Raeisi Estabragh MA, Salarpour S, Ohadi M, Dehghannoudeh G. Absorption enhancer approach for protein delivery by various routes of administration: a rapid review. Journal of Drug Targeting. 2023 Oct 21;31(9):950-961.  

https://doi.org/10.1080/1061186X.2023.2271680

  1. Mahmood I, Pettinato M. Impact of intrinsic & extrinsic factors on the pharmacokinetics of peptides: when is the assessment of certain factors warranted?. Antibodies. 2021 Dec 21;11(1):1-21. 

https://doi.org/10.3390/antib11010001

  1. Werle M, Föger F. Peroral peptide delivery: Peptidase inhibition as a key concept for commercial drug products. Bioorganic & medicinal chemistry. 2018 Jun 1;26(10):2906-2913.

https://doi.org/10.1016/j.bmc.2017.08.028

  1. Saldívar-Cerón HI, Vargas-Camacho JA, León-Cabrera S, Briseño-Díaz P, Castañeda-Ramírez AE, Muciño-Galicia AE, Díaz-Domínguez MR. Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights & Emerging Therapeutic Strategies. Scientia Pharmaceutica. 2025 Jun 11;93(2):1-24.

https://doi.org/10.3390/scipharm93020026

  1. Zeng J, Tang X, Qin D, Yu L, Zhou X, Feng C, Mi J, Pan H, Wu J, Huang B, Wu A. Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases. Journal of Nanobiotechnology. 2025 Oct 15;23(1):1-61.

https://doi.org/10.1186/s12951-025-03677-4

  1. Mehrdadi S. Lipid-based nanoparticles as oral drug delivery systems: Overcoming poor gastrointestinal absorption & enhancing bioavailability of peptide & protein therapeutics. Advanced Pharmaceutical Bulletin. 2023 Oct 14;14(1):48-66.

doi: 10.34172/apb.2024.016

  1. Kumar A, Sharma AK, Dutt R. A Review of Gastro-retentive Drug Delivery Systems for Antidiabetics & its present status. Research Journal of Pharmacy & Technology. 2021;14(1):538-546.

10.5958/0974-360X.2021.00098.6

  1. Tyagi P, Pechenov S, Subramony JA. Oral peptide delivery: Translational challenges due to physiological effects. Journal of Controlled Release. 2018 Oct 10;287:167-176.

https://doi.org/10.1016/j.jconrel.2018.08.032

  1. Woo Park J, Jin Kim S, Sup Kwag D, Kim S, Park J, Seok Youn Y, Han Bae Y, Seong Lee E. Multifunctional delivery systems for advanced oral uptake of peptide/protein drugs. Current pharmaceutical design. 2015 Jul 1;21(22):3097-3110. 

DOI: 10.2174/1381612821666150531163944

  1. Manzanares P, Gandía M, Garrigues S, Marcos JF. Improving health-promoting effects of food-derived bioactive peptides through rational design & oral delivery strategies. Nutrients. 2019 Oct 22;11(10):1-22.https://doi.org/10.3390/nu11102545
  2. Raeisi Estabragh MA, Bami MS, Ohadi M, Banat IM, Dehghannoudeh G. Carrier?based systems as strategies for oral delivery of therapeutic peptides & proteins: A mini?review. International Journal of Peptide Research & Therapeutics. 2021 Jun;27(2):1589-96.

https://doi.org/10.1007/s10989-021-10193-0

  1. Kh&ke A, Dhaybar S, Mandke A, Joshi A, Gholap AD, Rajput A. Ingestible devices for oral delivery of biotherapeutics: A Mini Review. Next Nanotechnology. 2025 Jan 1;7:1-10.

https://doi.org/10.1016/j.nxnano.2025.100195

  1. Holler N, Ruseska I, Schachner-Nedherer AL, Zimmer A, Petschacher C. Oral Treatment of Obesity by GLP-1 & Its Analogs. Pharmaceutics. 2025 Dec 10;17(12):1-67. https://doi.org/10.3390/pharmaceutics17121596
  2. Kim DH, Kim JE. Recent advances & trends in oral absorption enhancements of GLP-1 receptor agonist formulations. Journal of Pharmaceutical Investigation. 2025 Aug 26:1-7. https://doi.org/10.1007/s40005-025-00762-6
  3. Li Y, Yang D, Zhu C. Impact of sodium N-[8-(2-Hydroxybenzoyl) amino]-caprylate on intestinal permeability for notoginsenoside R1 & salvianolic acids in Caco-2 cells transport & rat pharmacokinetics. Molecules. 2018 Nov 16;23(11):1-14.  https://doi.org/10.3390/molecules23112990
  4. Eberle RJ, Sevenich M, Gering I, Scharbert L, Strodel B, Lakomek NA, Santur K, Mohrlu?der J, Coronado MA, Willbold D. Discovery of all-d-peptide inhibitors of SARS-CoV-2 3C-like  protease. ACS chemical biology. 2023 Jan 17;18(2):315-330.              https://doi.org/10.1021/acschembio.2c00735
  5. Chavda VP, Balar PC. Oral delivery of protein & peptide therapeutics. Progress in Molecular Biology & Translational Science. 2025 Jan 1;212:355-387.

https://doi.org/10.1016/bs.pmbts.2024.11.003

  1. Wang J, Yadav V, Smart AL, Tajiri S, Basit AW. Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Molecular pharmaceutics. 2015 Mar 2;12(3):966-973. 

https://doi.org/10.1021/mp500809f

  1. Kumar R, Islam T, Nurunnabi M. Mucoadhesive carriers for oral drug delivery. Journal of controlled release. 2022 Nov 1;351:504-559.                                                                            https://doi.org/10.1016/j.jconrel.2022.09.024
  2. Han Y, Gao Z, Chen L, Kang L, Huang W, Jin M, Wang Q, Bae YH. Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins. Acta Pharmaceutica Sinica B. 2019 Sep 1;9(5):902-922. 

https://doi.org/10.1016/j.apsb.2019.01.004

  1. Zizzari AT, Pliatsika D, Gall FM, Fischer T, Riedl R. New perspectives in oral peptide delivery. Drug discovery today. 2021 Apr 1;26(4):1097-105. 

https://doi.org/10.1016/j.drudis.2021.01.020

  1. Kanugo A, Misra A. New & novel approaches for enhancing the oral absorption & bioavailability of protein & peptides therapeutics. Therapeutic Delivery. 2020 Nov 1;11(11):713-732. 

https://doi.org/10.4155/tde-2020-0068

  1. Poudwal S, Misra A, Shende P. Role of lipid nanocarriers for enhancing oral absorption & bioavailability of insulin & GLP-1 receptor agonists. Journal of Drug Targeting. 2021 Sep 14;29(8):834-847. 

https://doi.org/10.1080/1061186X.2021.1894434

  1. Philippart M, Schmidt J, Bittner B. Oral delivery of therapeutic proteins & peptides: an overview of current technologies & recommendations for bridging from approved intravenous or subcutaneous administration to novel oral regimens. Drug research. 2016 Mar;66(03):113-120. 

10.1055/s-0035-1559654

  1. Karsdal MA, Riis BJ, Mehta N, Stern W, Arbit E, Christiansen C, Henriksen K. Lessons learned from the clinical development of oral peptides. British journal of clinical pharmacology. 2015 May;79(5):720-732. 

https://doi.org/10.1111/bcp.12557

  1. Wu TY. Strategies for designing synthetic immune agonists. Immunology. 2016 Aug;148(4):315-325. 

https://doi.org/10.1111/imm.12622Digital Object Identifier (DOI)

  1. Hall S, Isaacs D, Clements JN. Pharmacokinetics & clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist. Clinical pharmacokinetics. 2018 Dec;57(12):1529-1538.                                        

https://doi.org/10.1007/s40262-018-0668-z

  1. Liakos A, Karagiannis T, Avgerinos I, Malandris K, Tsapas A, Bekiari E. Management of type 2 diabetes in the new era. Hormones. 2023 Dec;22(4):677-684.

https://doi.org/10.1007/s42000-023-00488-w

  1. Jalleh RJ, Plummer MP, Marathe CS, Umapathysivam MM, Quast DR, Rayner CK, Jones KL, Wu T, Horowitz M, Nauck MA. Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists & tirzepatide. The Journal of Clinical Endocrinology & Metabolism. 2025 Jan;110(1):1-5. 

https://doi.org/10.1210/clinem/dgae719

  1. Brayden DJ, Maher S. Transient Permeation Enhancer®(TPE®) technology for oral delivery of octreotide: a technological evaluation. Expert opinion on drug delivery. 2021 Oct 3;18(10):1501-1512.     

https://doi.org/10.1080/17425247.2021.1942838

  1. Kristensen M, Nielsen HM. Cell-penetrating peptides as tools to enhance non-injectable delivery of biopharmaceuticals. Tissue Barriers. 2016 Apr 2;4(2):1-26. https://doi.org/10.1080/21688370.2016.1178369
  2. Sogaard PP, Lind M, Christiansen CR, Petersson K, Clauss A, Caffarel-Salvador E. Future perspectives of oral delivery of next generation therapies for treatment of skin diseases. Pharmaceutics. 2021 Oct 18;13(10):1-24.

https://doi.org/10.3390/pharmaceutics13101722

  1. Dadge SD, Mishra S, Khan S, Yadav S, Bhatta RS, Gayen JR. Oral Peptide Delivery Reimagined: Molecular Barriers, Formulation Strategies, & the Rise of Computational Design. International Journal of Peptide Research & Therapeutics. 2025 Sep 29;31(6):90-101.

https://doi.org/10.1007/s10989-025-10763-6

  1. Ma S, We L, Yang H, Deng S, Jevnikar AM. Emerging technologies to achieve oral delivery of GLP-1 & GLP-1 analogs for treatment of type 2 diabetes mellitus (T2DM). Canadian Journal of Biotechnology. 2017 Apr 1;1(1):1-10.

doi: 10.24870/cjb.2017-000107

  1. Li Y, Wang Y, Wei Q, Zheng X, Tang L, Kong D, Gong M. Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides. Scientific reports. 2015 Dec 11;5(1):1-9. 

https://doi.org/10.1038/srep18039

  1. Sangiorgi S, Albertini B, Bertoni S, Passerini N. An Overview on the Role of Ionic Liquids & Deep Eutectic Solvents in Oral Pharmaceuticals. Pharmaceutics. 2025 Feb 25;17(3):1-27.  https://doi.org/10.3390/pharmaceutics17030300
  2. Mantaj J, Vllasaliu D. Recent advances in the oral delivery of biologics. Pharm J. 2020 Jan 10;304(7933):2-7. 

10.1211/PJ.20202 07874.

  1. Porfiryeva NN, Zlotver I, Sosnik A. Combined Effect of Size & Charge on the Interaction of Nanoparticles with Mucus-Mimicking Mucin Hydrogels. Pharmaceuticals. 2025 Oct 5;18(10):1-15.  

https://doi.org/10.3390/ph18101498

  1. Wang S, Wang X, Luo Y, Liang Y. A comprehensive review of conventional & stimuli-responsive delivery systems for bioactive peptides: from food to biomedical applications. Advanced Composites & Hybrid Materials. 2025 Feb;8(1):1-31. 

https://doi.org/10.1007/s42114-024-01053-8

  1. Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics. Nature Reviews Drug Discovery. 2019 Jan;18(1):19-40.                                                                          https://doi.org/10.1038/nrd.2018.183
  2. Wang Z, Wang J, Kahkoska AR, Buse JB, Gu Z. Developing insulin delivery devices with glucose responsiveness. Trends in pharmacological sciences. 2021 Jan 1;42(1):31-44.  https://doi.org/10.1016/j.tips.2020.11.002
  3. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology & drug delivery design. Pharmaceutics. 2023 Jul 10;15(7):1-46.  https://doi.org/10.3390/pharmaceutics15071916
  4. Gangwal A, Lavecchia A. Artificial intelligence in anti-obesity drug discovery: unlocking next-generation therapeutics. Drug Discovery Today. 2025 Mar 17:1-16. 
    https://doi.org/10.1016/j.drudis.2025.104333
  5. Zane D, Feldman PL, Sawyer T, Sobol Z, Hawes J. Development & Regulatory Challenges for Peptide Therapeutics. International Journal of toxicology. 2020;40(2):108-124. doi:10.1177/1091581820977846
  6. Maher S, Geoghegan C, Brayden DJ. Intestinal permeation enhancers to improve oral bioavailability of macromolecules: reasons for low efficacy in humans. Expert Opinion on Drug Delivery. 2021 Feb 1;18(2):273-300.

https://doi.org/10.1080/17425247.2021.1825375

  1. McCartney F, Gleeson JP, Brayden DJ. Safety concerns over the use of intestinal permeation enhancers: A mini-review. Tissue barriers. 2016 Apr 2;4(2):1-22.               https://doi.org/10.1080/21688370.2016.1176822
  2. Koziolek M, Augustijns P, Berger C, Cristofoletti R, Dahlgren D, Keemink J, Matsson P, McCartney F, Metzger M, Mezler M, Niessen J. Challenges in permeability assessment for oral drug product development. Pharmaceutics. 2023 Sep 28;15(10):1-38.   https://doi.org/10.3390/pharmaceutics15102397
  3. Xiong Y, Wang J, Zhou X, Li X. The Development of a Stable Peptide-Loaded Long-Acting Injection Formulation through a Comprehensive Understanding of Peptide Degradation Mechanisms: A QbD-Based Approach. Pharmaceutics. 2024 Feb 13;16(2):1-18.  https://doi.org/10.3390/pharmaceutics16020266
  4. Baekdal TA, Breitschaft A, Donsmark M, Maarbjerg SJ, Søndergaard FL, Borregaard J. Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation. Diabetes Therapy. 2021 Jul;12(7):1915-1927. https://doi.org/10.1007/s13300-021-01078-y
  5. De Groot AS, Mattei A, Gabriel B, Calderini J, Roberts BJ, Lelias S, McAllister M, Boyle C, Martin W, Richard G. Immunogenicity of Generic Peptide Impurities: Current Orthogonal Approaches. Pharmaceutical Research. 2025 May;42(5):805-818.  https://doi.org/10.1007/s11095-025-03843-1

Reference

  1. Drucker DJ. GLP-1 physiology informs the pharmacotherapy of obesity. Molecular metabolism. 2022 Mar 1;57:1-13.

https://doi.org/10.1016/j.molmet.2021.101351

  1. Müller TD, Finan B, Bloom SR, D'Alessio D, Drucker DJ, Flatt PR, Fritsche A, Gribble F, Grill HJ, Habener JF, Holst JJ. Glucagon-like peptide 1 (GLP-1). Molecular metabolism. 2019 Dec 1;30:72-130.

https://doi.org/10.1016/j.molmet.2019.09.010

  1. Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art. Molecular metabolism. 2021 Apr 1;46:1-26. https://doi.org/10.1016/j.molmet.2020.101102
  2. Klen J, Dolžan V. Glucagon-like peptide-1 receptor agonists in the management of type 2 diabetes mellitus & obesity: the impact of pharmacological properties & genetic factors. International journal of molecular sciences. 2022 Mar 22;23(7):1-18.

https://doi.org/10.3390/ijms23073451

  1. Helmstädter J, Keppeler K, Küster L, Münzel T, Daiber A, Steven S. Glucagon?like peptide?1 (GLP?1) receptor agonists & their cardiovascular benefits—The role of the GLP?1 receptor. British journal of pharmacology. 2022 Feb;179(4):659-676.  

https://doi.org/10.1111/bph.15462

  1. Myers JT, Dam JV, Imran M, Hashim M, Dhalla AK. Preference for a novel oral alternative to parenterally administered medications. Patient preference & adherence. 2024 Dec 31:1547-1562.

https://doi.org/10.2147/PPA.S463354

  1. Matza LS, Cutts KN, Stewart KD, Norrbacka K, García-Pérez LE, Boye KS. Health state utilities associated with treatment process for oral & injectable GLP-1 receptor agonists for type 2 diabetes. Quality of Life Research. 2021 Jul;30(7):2033-2043.

https://doi.org/10.1007/s11136-021-02808-2

  1. Zhang Y, Zhang H, Ghosh D, Williams III RO. Just how prevalent are peptide therapeutic products? A critical review. International journal of pharmaceutics. 2020 Sep 25;587:1-47. https://doi.org/10.1016/j.ijpharm.2020.119491
  2. Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W, Hu Y, Shi J. Advance in peptide-based drug development: delivery platforms, therapeutics & vaccines. Signal Transduction & Targeted Therapy. 2025 Mar 5;10(1):1-56.

https://doi.org/10.1038/s41392-024-02107-5

  1. Baral KC, Choi KY. Barriers & strategies for oral peptide & protein therapeutics delivery: update on clinical advances. Pharmaceutics. 2025 Mar 21;17(4):1-30. https://doi.org/10.3390/pharmaceutics17040397
  2. Yang X, Lin R, Feng C, Kang Q, Yu P, Deng Y, Jin Y. Research Progress on Peptide Drugs for Type 2 Diabetes & the Possibility of Oral Administration. Pharmaceutics. 2024 Oct 23;16(11):1-24.

https://doi.org/10.3390/pharmaceutics16111353

  1. McBrayer DN, Tal?Gan Y. Recent advances in GLP?1 receptor agonists for use in diabetes mellitus. Drug development research. 2017 Sep;78(6):292-309.

 https://doi.org/10.1002/ddr.21404

  1. Gleeson JP, Fein KC, Whitehead KA. Oral delivery of peptide therapeutics in infants: Challenges & opportunities. Advanced drug delivery reviews. 2021 Mar 25;173:1-29.

10.1016/j.addr.2021.03.011

  1. Wu T, Wong CK, Lui DT, Wong SK, Lam CL, Chung MS, McAllister DA, Welbourn R, Dixon JB. Bariatric surgery, novel glucose-lowering agents, & insulin for type 2 diabetes & obesity: Bayesian network meta-analysis of randomized controlled trials. BJS open. 2023 Aug;7(4):1-11.

https://doi.org/10.1093/bjsopen/zrad077

  1. Pechenov S, Revell J, Will S, Naylor J, Tyagi P, Patel C, Liang L, Tseng L, Huang Y, Rosenbaum AI, Balic K. Development of an orally delivered GLP-1 receptor agonist through peptide engineering & drug delivery to treat chronic disease. Scientific Reports. 2021 Nov 18;11(1):1-15.

https://doi.org/10.1038/s41598-021-01750-0

  1. Zhao X, Wang M, Wen Z, Lu Z, Cui L, Fu C, Xue H, Liu Y, Zhang Y. GLP-1 receptor agonists: beyond their pancreatic effects. Frontiers in endocrinology. 2021 Aug 23;12:1-19.  https://doi.org/10.3389/fendo.2021.721135
  2. Borner T, Tinsley IC, Doyle RP, Hayes MR, De Jonghe BC. Glucagon?like peptide?1 in diabetes care: Can glycaemic control be achieved without nausea & vomiting?. British journal of pharmacology. 2022 Feb;179(4):542-556.

https://doi.org/10.1111/bph.15647

  1. Kuthati Y, Davuluri VN, Wong CS. Therapeutic effects of GLP-1 receptor agonists & DPP-4 inhibitors in neuropathic pain: mechanisms & clinical implications. Biomolecules. 2025 Apr 26;15(5):1-17. 

https://doi.org/10.3390/biom15050622

  1. Danowitz M, De Leon DD. The role of GLP-1 signaling in hypoglycemia due to hyperinsulinism. Frontiers in Endocrinology. 2022 Mar 24;13:1-7.  

https://doi.org/10.3389/fendo.2022.863184

  1. Qin J, Song L. Glucagon-like peptide-1 (GLP-1) receptor agonists & cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials. BMC endocrine disorders. 2022 May 12;22(1):1-7.  

10.1186/s12902-022-01036-0

  1. Min JS, Jo SJ, Lee S, Kim DY, Kim DH, Lee CB, Bae SK. A Comprehensive Review on the Pharmacokinetics & Drug− Drug Interactions of Approved GLP-1 Receptor Agonists & a Dual GLP-1/GIP Receptor Agonist. Drug Design, Development & Therapy. 2025 Dec 31:3509-3537. 

https://doi.org/10.2147/DDDT.S506957

  1. Aroda VR, Blonde L, Pratley RE. A new era for oral peptides: SNAC & the development of oral semaglutide for the treatment of type 2 diabetes. Reviews in Endocrine & Metabolic Disorders. 2022 Oct;23(5):979-994. 

https://doi.org/10.1007/s11154-022-09735-8

  1. Ryan D, Acosta A. GLP?1 receptor agonists: Nonglycemic clinical effects in weight loss & beyond. Obesity. 2015 Jun;23(6):1119-1129.  

10.1002/oby.21107

  1. Johnson H, Huang D, Liu V, Ammouri MA, Jacobs C, El-Osta A. Impact of digital engagement on weight loss outcomes in obesity management among individuals using GLP-1 & dual GLP-1/GIP receptor agonist therapy: retrospective cohort service evaluation study. Journal of Medical Internet Research. 2025 Mar 31;27:1-18.

10.2196/69466

  1. Antza C, Nirantharakumar K, Doundoulakis I, Tahrani AA, Toulis KA. The development of an oral GLP-1 receptor agonist for the management of type 2 diabetes: evidence to date. Drug design, development & therapy. 2019 Aug 22:2985-2996. 

https://doi.org/10.2147/DDDT.S166765

  1. Maher S, Ryan B, Duffy A, Brayden DJ. Formulation strategies to improve oral peptide delivery. Pharmaceutical patent analyst. 2014 May 1;3(3):313-336.   

https://doi.org/10.4155/ppa.14.15

  1. Liu M, Svirskis D, Proft T, Loh J, Yin N, Li H, Li D, Zhou Y, Chen S, Song L, Chen G. Progress in peptide & protein therapeutics: Challenges & strategies. Acta Pharmaceutica Sinica B. 2025 Oct 25.1-40 

https://doi.org/10.1016/j.apsb.2025.10.026

  1. Richard J. Challenges in oral peptide delivery: lessons learnt from the clinic & future prospects. Therapeutic Delivery. 2017 Jul 1;8(8):663-84.  https://doi.org/10.4155/tde-2017-0024
  2. Choe HJ, Cho YM. Peptidyl & non-peptidyl oral glucagon-like peptide-1 receptor agonists. Endocrinology & Metabolism. 2021 Feb 24;36(1):22-29.   https://doi.org/10.3803/EnM.2021.102
  3. Mehrotra S, Bg PK, Nayak PG, Joseph A, Manikkath J. Recent progress in the oral delivery of therapeutic peptides & proteins: overview of pharmaceutical strategies to overcome absorption hurdles. Advanced Pharmaceutical Bulletin. 2023 Aug 26;14(1):11-33.     

10.34172/apb.2024.009

  1. Liu K, Huang Y, Wang T, Mu R, Rosenbaum AI. In-vitro metabolite identification for MEDI7219, an oral GLP-1 analog, using LC-MS/MS with CID & EAD approaches. Bioanalysis. 2025 Jul 3;17(13):881-888.  

https://doi.org/10.1080/17576180.2025.2535954

  1. Patel S, Vyas VK, Mehta PJ. A review on forced degradation strategies to establish the stability of therapeutic peptide formulations. International Journal of Peptide Research & Therapeutics. 2023 Feb 13;29(2):1-22.  https://doi.org/10.1007/s10989-023-10492-8
  2. Verma S, Go& UK, Husain A, Katekar RA, Garg R, Gayen JR. Challenges of peptide & protein drug delivery by oral route: Current strategies to improve the bioavailability. Drug development research. 2021 Nov;82(7):927-944.  

https://doi.org/10.1002/ddr.21832

  1. Bardonnet PL, Niu Z, Pessi J, Kazakou M, Raptis K, McCabe R, Toftlev A, Rebollo R, Wang Z, Fan L, Mortensen NR. An effort to enhance the clinical translatability of caprate-based tablet formulations in gastric peptide delivery. Drug Delivery & Translational Research. 2025 Sep 23:1-4.  

https://doi.org/10.1007/s13346-025-01978-7

  1. Rocho? J, Kalinowski P, Szymanek-Majchrzak K, Gr?t M. Role of gut-liver axis & glucagon-like peptide-1 receptor agonists in the treatment of metabolic dysfunction-associated fatty liver disease. World Journal of Gastroenterology. 2024 Jun 21;30(23):2964-2980.                 

10.3748/wjg.v30.i23.2964

  1. Komin A, Bogorad MI, Lin R, Cui H, Searson PC, Hristova K. A peptide for transcellular cargo delivery: Structure-function relationship & mechanism of action. Journal of Controlled Release. 2020 Aug 10;324:633-643.               

https://doi.org/10.1016/j.jconrel.2020.05.030

  1. Leal J, Dong T, Taylor A, Siegrist E, Gao F, Smyth HD, Ghosh D. Mucus-penetrating phage-displayed peptides for improved transport across a mucus-like model. International journal of pharmaceutics. 2018 Dec 20;553(1-2):57-64. 

https://doi.org/10.1016/j.ijpharm.2018.09.055

  1. Boegh M, Nielsen HM. Mucus as a barrier to drug delivery–understanding & mimicking the barrier properties. Basic & clinical pharmacology & toxicology. 2015 Mar;116(3):179-86.             https://doi.org/10.1111/bcpt.12342
  2. Asano D, Takakusa H, Nakai D. Oral absorption of middle-to-large molecules & its improvement, with a focus on new modality drugs. Pharmaceutics. 2023 Dec 28;16(1):1-27. https://doi.org/10.3390/pharmaceutics16010047
  3. Amigo L, Hernández-Ledesma B. Current evidence on the bioavailability of food bioactive peptides. Molecules. 2020 Sep 29;25(19):1-36.  

https://doi.org/10.3390/molecules25194479

  1. Khan TT, Sheikh Z, Maleknia S, Oveissi F, Fathi A, Abrams T, Ong HX, Traini D. Intranasal delivery of glucagon-like peptide-1 to the brain for obesity treatment: opportunities & challenges. Expert Opinion on Drug Delivery. 2024 Jul 2;21(7):1081-101.  https://doi.org/10.1080/17425247.2024.2387110
  2. Janssen G, Christis C, Kooy-Winkelaar Y, Edens L, Smith D, van Veelen P, Koning F. Ineffective degradation of immunogenic gluten epitopes by currently available digestive enzyme supplements. PloS one. 2015 Jun 1;10(6):1-15. 

https://doi.org/10.1371/journal.pone.0128065

  1. Zapadka KL, Becher FJ, Gomes dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface focus. 2017 Dec 6;7(6):1-18.  https://doi.org/10.1098/rsfs.2017.0030
  2. Kadel S, Pellerin G, Thibodeau J, Perreault V, Lainé C, Bazinet L. How molecular weight cut-offs & physicochemical properties of polyether sulfone membranes affect peptide migration & selectivity during electrodialysis with filtration membranes. Membranes. 2019 Nov 13;9(11):1-18. 

https://doi.org/10.3390/membranes9110153

  1. Roxas JL, Viswanathan VK. Modulation of intestinal paracellular transport by bacterial pathogens. Comprehensive Physiology. 2018 Apr 17;8(2):823-842.  

https://doi.org/10.1002/j.2040-4603.2018.tb00025.x

  1. Wang CM, Fernez MT, Woolston BM, Carrier RL. Native gastrointestinal mucus: Critical features & techniques for studying interactions with drugs, drug carriers, & bacteria. Advanced drug delivery reviews. 2023 Sep 1;200:1-34.

 https://doi.org/10.1016/j.addr.2023.114966

  1. Larder CE, Iskandar MM, Kubow S. Assessment of bioavailability after in vitro digestion & first pass metabolism of bioactive peptides from collagen hydrolysates. Current Issues in Molecular Biology. 2021 Oct 13;43(3):1592-605. 

https://doi.org/10.3390/cimb43030113

  1. Chakrabarti S, Guha S, Majumder K. Food-derived bioactive peptides in human health: Challenges & opportunities. Nutrients. 2018 Nov 12;10(11):1-17.                                      https://doi.org/10.3390/nu10111738
  2. Xu Y, Drucker DJ, Traverso G, Beloqui A. Innovative molecules & delivery technologies enabling the future of GLP-1-based therapies. Endocrine reviews. 2026 Feb;47(1):1-23.   https://doi.org/10.1210/endrev/bnaf027
  3. Drucker DJ. Advances in oral peptide therapeutics. Nature reviews Drug discovery. 2020 Apr;19(4):277-289.    

https://doi.org/10.1038/s41573-019-0053-0

  1. Nicze M, Borówka M, Dec A, Niemiec A, Bu?dak ?, Okopie? B. The current & promising oral delivery methods for protein-& peptide-based drugs. International Journal of Molecular Sciences. 2024 Jan 9;25(2):1-29.  

https://doi.org/10.3390/ijms25020815

  1. Solis-Herrera C, Kane MP, Triplitt C. Current understanding of sodium n-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: The oral semaglutide experience. Clinical Diabetes. 2024 Jan 1;42(1):74-86. 

https://doi.org/10.2337/cd22-0118

  1. Tran H, ElSayed ME. Progress & limitations of oral peptide delivery as a potentially transformative therapy. Expert Opinion on Drug Delivery. 2022 Feb 1;19(2):163-178.

https://doi.org/10.1080/17425247.2022.2051476

  1. Salehi T, Raeisi Estabragh MA, Salarpour S, Ohadi M, Dehghannoudeh G. Absorption enhancer approach for protein delivery by various routes of administration: a rapid review. Journal of Drug Targeting. 2023 Oct 21;31(9):950-961.  

https://doi.org/10.1080/1061186X.2023.2271680

  1. Mahmood I, Pettinato M. Impact of intrinsic & extrinsic factors on the pharmacokinetics of peptides: when is the assessment of certain factors warranted?. Antibodies. 2021 Dec 21;11(1):1-21. 

https://doi.org/10.3390/antib11010001

  1. Werle M, Föger F. Peroral peptide delivery: Peptidase inhibition as a key concept for commercial drug products. Bioorganic & medicinal chemistry. 2018 Jun 1;26(10):2906-2913.

https://doi.org/10.1016/j.bmc.2017.08.028

  1. Saldívar-Cerón HI, Vargas-Camacho JA, León-Cabrera S, Briseño-Díaz P, Castañeda-Ramírez AE, Muciño-Galicia AE, Díaz-Domínguez MR. Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights & Emerging Therapeutic Strategies. Scientia Pharmaceutica. 2025 Jun 11;93(2):1-24.

https://doi.org/10.3390/scipharm93020026

  1. Zeng J, Tang X, Qin D, Yu L, Zhou X, Feng C, Mi J, Pan H, Wu J, Huang B, Wu A. Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases. Journal of Nanobiotechnology. 2025 Oct 15;23(1):1-61.

https://doi.org/10.1186/s12951-025-03677-4

  1. Mehrdadi S. Lipid-based nanoparticles as oral drug delivery systems: Overcoming poor gastrointestinal absorption & enhancing bioavailability of peptide & protein therapeutics. Advanced Pharmaceutical Bulletin. 2023 Oct 14;14(1):48-66.

doi: 10.34172/apb.2024.016

  1. Kumar A, Sharma AK, Dutt R. A Review of Gastro-retentive Drug Delivery Systems for Antidiabetics & its present status. Research Journal of Pharmacy & Technology. 2021;14(1):538-546.

10.5958/0974-360X.2021.00098.6

  1. Tyagi P, Pechenov S, Subramony JA. Oral peptide delivery: Translational challenges due to physiological effects. Journal of Controlled Release. 2018 Oct 10;287:167-176.

https://doi.org/10.1016/j.jconrel.2018.08.032

  1. Woo Park J, Jin Kim S, Sup Kwag D, Kim S, Park J, Seok Youn Y, Han Bae Y, Seong Lee E. Multifunctional delivery systems for advanced oral uptake of peptide/protein drugs. Current pharmaceutical design. 2015 Jul 1;21(22):3097-3110. 

DOI: 10.2174/1381612821666150531163944

  1. Manzanares P, Gandía M, Garrigues S, Marcos JF. Improving health-promoting effects of food-derived bioactive peptides through rational design & oral delivery strategies. Nutrients. 2019 Oct 22;11(10):1-22.https://doi.org/10.3390/nu11102545
  2. Raeisi Estabragh MA, Bami MS, Ohadi M, Banat IM, Dehghannoudeh G. Carrier?based systems as strategies for oral delivery of therapeutic peptides & proteins: A mini?review. International Journal of Peptide Research & Therapeutics. 2021 Jun;27(2):1589-96.

https://doi.org/10.1007/s10989-021-10193-0

  1. Kh&ke A, Dhaybar S, Mandke A, Joshi A, Gholap AD, Rajput A. Ingestible devices for oral delivery of biotherapeutics: A Mini Review. Next Nanotechnology. 2025 Jan 1;7:1-10.

https://doi.org/10.1016/j.nxnano.2025.100195

  1. Holler N, Ruseska I, Schachner-Nedherer AL, Zimmer A, Petschacher C. Oral Treatment of Obesity by GLP-1 & Its Analogs. Pharmaceutics. 2025 Dec 10;17(12):1-67. https://doi.org/10.3390/pharmaceutics17121596
  2. Kim DH, Kim JE. Recent advances & trends in oral absorption enhancements of GLP-1 receptor agonist formulations. Journal of Pharmaceutical Investigation. 2025 Aug 26:1-7. https://doi.org/10.1007/s40005-025-00762-6
  3. Li Y, Yang D, Zhu C. Impact of sodium N-[8-(2-Hydroxybenzoyl) amino]-caprylate on intestinal permeability for notoginsenoside R1 & salvianolic acids in Caco-2 cells transport & rat pharmacokinetics. Molecules. 2018 Nov 16;23(11):1-14.  https://doi.org/10.3390/molecules23112990
  4. Eberle RJ, Sevenich M, Gering I, Scharbert L, Strodel B, Lakomek NA, Santur K, Mohrlu?der J, Coronado MA, Willbold D. Discovery of all-d-peptide inhibitors of SARS-CoV-2 3C-like  protease. ACS chemical biology. 2023 Jan 17;18(2):315-330.              https://doi.org/10.1021/acschembio.2c00735
  5. Chavda VP, Balar PC. Oral delivery of protein & peptide therapeutics. Progress in Molecular Biology & Translational Science. 2025 Jan 1;212:355-387.

https://doi.org/10.1016/bs.pmbts.2024.11.003

  1. Wang J, Yadav V, Smart AL, Tajiri S, Basit AW. Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs. Molecular pharmaceutics. 2015 Mar 2;12(3):966-973. 

https://doi.org/10.1021/mp500809f

  1. Kumar R, Islam T, Nurunnabi M. Mucoadhesive carriers for oral drug delivery. Journal of controlled release. 2022 Nov 1;351:504-559.                                                                            https://doi.org/10.1016/j.jconrel.2022.09.024
  2. Han Y, Gao Z, Chen L, Kang L, Huang W, Jin M, Wang Q, Bae YH. Multifunctional oral delivery systems for enhanced bioavailability of therapeutic peptides/proteins. Acta Pharmaceutica Sinica B. 2019 Sep 1;9(5):902-922. 

https://doi.org/10.1016/j.apsb.2019.01.004

  1. Zizzari AT, Pliatsika D, Gall FM, Fischer T, Riedl R. New perspectives in oral peptide delivery. Drug discovery today. 2021 Apr 1;26(4):1097-105. 

https://doi.org/10.1016/j.drudis.2021.01.020

  1. Kanugo A, Misra A. New & novel approaches for enhancing the oral absorption & bioavailability of protein & peptides therapeutics. Therapeutic Delivery. 2020 Nov 1;11(11):713-732. 

https://doi.org/10.4155/tde-2020-0068

  1. Poudwal S, Misra A, Shende P. Role of lipid nanocarriers for enhancing oral absorption & bioavailability of insulin & GLP-1 receptor agonists. Journal of Drug Targeting. 2021 Sep 14;29(8):834-847. 

https://doi.org/10.1080/1061186X.2021.1894434

  1. Philippart M, Schmidt J, Bittner B. Oral delivery of therapeutic proteins & peptides: an overview of current technologies & recommendations for bridging from approved intravenous or subcutaneous administration to novel oral regimens. Drug research. 2016 Mar;66(03):113-120. 

10.1055/s-0035-1559654

  1. Karsdal MA, Riis BJ, Mehta N, Stern W, Arbit E, Christiansen C, Henriksen K. Lessons learned from the clinical development of oral peptides. British journal of clinical pharmacology. 2015 May;79(5):720-732. 

https://doi.org/10.1111/bcp.12557

  1. Wu TY. Strategies for designing synthetic immune agonists. Immunology. 2016 Aug;148(4):315-325. 

https://doi.org/10.1111/imm.12622Digital Object Identifier (DOI)

  1. Hall S, Isaacs D, Clements JN. Pharmacokinetics & clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist. Clinical pharmacokinetics. 2018 Dec;57(12):1529-1538.                                        

https://doi.org/10.1007/s40262-018-0668-z

  1. Liakos A, Karagiannis T, Avgerinos I, Malandris K, Tsapas A, Bekiari E. Management of type 2 diabetes in the new era. Hormones. 2023 Dec;22(4):677-684.

https://doi.org/10.1007/s42000-023-00488-w

  1. Jalleh RJ, Plummer MP, Marathe CS, Umapathysivam MM, Quast DR, Rayner CK, Jones KL, Wu T, Horowitz M, Nauck MA. Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists & tirzepatide. The Journal of Clinical Endocrinology & Metabolism. 2025 Jan;110(1):1-5. 

https://doi.org/10.1210/clinem/dgae719

  1. Brayden DJ, Maher S. Transient Permeation Enhancer®(TPE®) technology for oral delivery of octreotide: a technological evaluation. Expert opinion on drug delivery. 2021 Oct 3;18(10):1501-1512.     

https://doi.org/10.1080/17425247.2021.1942838

  1. Kristensen M, Nielsen HM. Cell-penetrating peptides as tools to enhance non-injectable delivery of biopharmaceuticals. Tissue Barriers. 2016 Apr 2;4(2):1-26. https://doi.org/10.1080/21688370.2016.1178369
  2. Sogaard PP, Lind M, Christiansen CR, Petersson K, Clauss A, Caffarel-Salvador E. Future perspectives of oral delivery of next generation therapies for treatment of skin diseases. Pharmaceutics. 2021 Oct 18;13(10):1-24.

https://doi.org/10.3390/pharmaceutics13101722

  1. Dadge SD, Mishra S, Khan S, Yadav S, Bhatta RS, Gayen JR. Oral Peptide Delivery Reimagined: Molecular Barriers, Formulation Strategies, & the Rise of Computational Design. International Journal of Peptide Research & Therapeutics. 2025 Sep 29;31(6):90-101.

https://doi.org/10.1007/s10989-025-10763-6

  1. Ma S, We L, Yang H, Deng S, Jevnikar AM. Emerging technologies to achieve oral delivery of GLP-1 & GLP-1 analogs for treatment of type 2 diabetes mellitus (T2DM). Canadian Journal of Biotechnology. 2017 Apr 1;1(1):1-10.

doi: 10.24870/cjb.2017-000107

  1. Li Y, Wang Y, Wei Q, Zheng X, Tang L, Kong D, Gong M. Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides. Scientific reports. 2015 Dec 11;5(1):1-9. 

https://doi.org/10.1038/srep18039

  1. Sangiorgi S, Albertini B, Bertoni S, Passerini N. An Overview on the Role of Ionic Liquids & Deep Eutectic Solvents in Oral Pharmaceuticals. Pharmaceutics. 2025 Feb 25;17(3):1-27.  https://doi.org/10.3390/pharmaceutics17030300
  2. Mantaj J, Vllasaliu D. Recent advances in the oral delivery of biologics. Pharm J. 2020 Jan 10;304(7933):2-7. 

10.1211/PJ.20202 07874.

  1. Porfiryeva NN, Zlotver I, Sosnik A. Combined Effect of Size & Charge on the Interaction of Nanoparticles with Mucus-Mimicking Mucin Hydrogels. Pharmaceuticals. 2025 Oct 5;18(10):1-15.  

https://doi.org/10.3390/ph18101498

  1. Wang S, Wang X, Luo Y, Liang Y. A comprehensive review of conventional & stimuli-responsive delivery systems for bioactive peptides: from food to biomedical applications. Advanced Composites & Hybrid Materials. 2025 Feb;8(1):1-31. 

https://doi.org/10.1007/s42114-024-01053-8

  1. Anselmo AC, Gokarn Y, Mitragotri S. Non-invasive delivery strategies for biologics. Nature Reviews Drug Discovery. 2019 Jan;18(1):19-40.                                                                          https://doi.org/10.1038/nrd.2018.183
  2. Wang Z, Wang J, Kahkoska AR, Buse JB, Gu Z. Developing insulin delivery devices with glucose responsiveness. Trends in pharmacological sciences. 2021 Jan 1;42(1):31-44.  https://doi.org/10.1016/j.tips.2020.11.002
  3. Vora LK, Gholap AD, Jetha K, Thakur RR, Solanki HK, Chavda VP. Artificial intelligence in pharmaceutical technology & drug delivery design. Pharmaceutics. 2023 Jul 10;15(7):1-46.  https://doi.org/10.3390/pharmaceutics15071916
  4. Gangwal A, Lavecchia A. Artificial intelligence in anti-obesity drug discovery: unlocking next-generation therapeutics. Drug Discovery Today. 2025 Mar 17:1-16. 
    https://doi.org/10.1016/j.drudis.2025.104333
  5. Zane D, Feldman PL, Sawyer T, Sobol Z, Hawes J. Development & Regulatory Challenges for Peptide Therapeutics. International Journal of toxicology. 2020;40(2):108-124. doi:10.1177/1091581820977846
  6. Maher S, Geoghegan C, Brayden DJ. Intestinal permeation enhancers to improve oral bioavailability of macromolecules: reasons for low efficacy in humans. Expert Opinion on Drug Delivery. 2021 Feb 1;18(2):273-300.

https://doi.org/10.1080/17425247.2021.1825375

  1. McCartney F, Gleeson JP, Brayden DJ. Safety concerns over the use of intestinal permeation enhancers: A mini-review. Tissue barriers. 2016 Apr 2;4(2):1-22.               https://doi.org/10.1080/21688370.2016.1176822
  2. Koziolek M, Augustijns P, Berger C, Cristofoletti R, Dahlgren D, Keemink J, Matsson P, McCartney F, Metzger M, Mezler M, Niessen J. Challenges in permeability assessment for oral drug product development. Pharmaceutics. 2023 Sep 28;15(10):1-38.   https://doi.org/10.3390/pharmaceutics15102397
  3. Xiong Y, Wang J, Zhou X, Li X. The Development of a Stable Peptide-Loaded Long-Acting Injection Formulation through a Comprehensive Understanding of Peptide Degradation Mechanisms: A QbD-Based Approach. Pharmaceutics. 2024 Feb 13;16(2):1-18.  https://doi.org/10.3390/pharmaceutics16020266
  4. Baekdal TA, Breitschaft A, Donsmark M, Maarbjerg SJ, Søndergaard FL, Borregaard J. Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation. Diabetes Therapy. 2021 Jul;12(7):1915-1927. https://doi.org/10.1007/s13300-021-01078-y
  5. De Groot AS, Mattei A, Gabriel B, Calderini J, Roberts BJ, Lelias S, McAllister M, Boyle C, Martin W, Richard G. Immunogenicity of Generic Peptide Impurities: Current Orthogonal Approaches. Pharmaceutical Research. 2025 May;42(5):805-818.  https://doi.org/10.1007/s11095-025-03843-1

Photo
Patil Rajvardhan
Corresponding author

Research Scholar at Department of Pharmaceutics, Dr. Shivajirao Kadam College of Pharmacy, Kasabe - Digraj, Maharashtra, India

Photo
Patil Snehit
Co-author

Research Scholar at Department of Pharmaceutics, Dr. Shivajirao Kadam College of Pharmacy, Kasabe - Digraj, Maharashtra, India

Photo
Kadam Swapnil
Co-author

Research Scholar at Department of Pharmaceutics, Dr. Shivajirao Kadam College of Pharmacy, Kasabe - Digraj, Maharashtra, India

Photo
Sulgudle Shivraj
Co-author

Research Scholar at Department of Pharmaceutics, Maratha Vidya Prasarak Samaj College of Pharmacy Nashik, Maharashtra, India

Photo
Dr. Gejage Santosh
Co-author

Associate Professor Department of Pharmaceutics, Dr. Shivajirao Kadam College of Pharmacy, Kasabe - Digraj, Maharashtra, India

Patil Rajvardhan, Patil Snehit, Kadam Swapnil, Sulgudle Shivraj, Dr. Gejage Santosh, Oral Delivery Challenges & Formulation Strategies for Glucagon Like Peptide-1 Receptor Agonists, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 2, 1819-1841. https://doi.org/10.5281/zenodo.18620126

More related articles
Artificial Intelligence and Machine Learning in Ph...
Sanjay R, SarathKumar R, Koushik Kumaran E P, Hariharasudhan B...
Lifecycle Analysis of Medicines Withdrawn, Restric...
Dr. Md Sayeed Anwar, Dr. Shyam Lal Yadav, Dr. Lakshyadeep Choud...
Formulation And Evaluation of Fast Dissolving Tabl...
Aditya Patil, Pranita Bhoite , Shubham Patil, Digvijay Kesare, Dr...
View more
Download PDF
Related Articles
Clinical Efficacy of Grape Seed Extract as an Adjuvant to Scaling and Root Plani...
Dr. Numrah Haque, Dr. Gurpreet Kaur, Dr. Navneet Kaur, Dr. Rakshita Sharma...
Solubility Enhancement Techniques for Poorly Water-Soluble Drugs...
Ayusha, Anshul Thakur, Neetu Sharma, Dr. Isha Rani, Arpit Sharma, Nitesh, Mohit Dhiman, Arush, Anshu...
7-Hydroxy-4-Methylcoumarin Derivatives: A Multitargeted Ligand for the Managemen...
Chithra P, Arul K...
Formulation and Evaluation of Suspension of Urtica Dioica (Nettle) Powder to Tre...
Rutik Antarkar, Vidya Kale...
Artificial Intelligence and Machine Learning in Pharmacovigilance: Adverse Drug ...
Sanjay R, SarathKumar R, Koushik Kumaran E P, Hariharasudhan B, Madhavan P, Vedhanayagi Gunasek...
More related articles
Artificial Intelligence and Machine Learning in Pharmacovigilance: Adverse Drug ...
Sanjay R, SarathKumar R, Koushik Kumaran E P, Hariharasudhan B, Madhavan P, Vedhanayagi Gunasek...
Lifecycle Analysis of Medicines Withdrawn, Restricted, or Label Updated Due to S...
Dr. Md Sayeed Anwar, Dr. Shyam Lal Yadav, Dr. Lakshyadeep Choudhary, Dr. Khushi Gupta, Dr. Piyus...
Formulation And Evaluation of Fast Dissolving Tablet of Ibuprofen Using Fenugree...
Aditya Patil, Pranita Bhoite , Shubham Patil, Digvijay Kesare, Dr. Abhijeet Kulkarni, Dhanashree Jir...
View more
Artificial Intelligence and Machine Learning in Pharmacovigilance: Adverse Drug ...
Sanjay R, SarathKumar R, Koushik Kumaran E P, Hariharasudhan B, Madhavan P, Vedhanayagi Gunasek...
Lifecycle Analysis of Medicines Withdrawn, Restricted, or Label Updated Due to S...
Dr. Md Sayeed Anwar, Dr. Shyam Lal Yadav, Dr. Lakshyadeep Choudhary, Dr. Khushi Gupta, Dr. Piyus...
Formulation And Evaluation of Fast Dissolving Tablet of Ibuprofen Using Fenugree...
Aditya Patil, Pranita Bhoite , Shubham Patil, Digvijay Kesare, Dr. Abhijeet Kulkarni, Dhanashree Jir...
View more

Copyright © 2026 IJPS. All rights reserved